Efficacy and Safety of Moxonidine in Indian Patients

This study has been completed.
Sponsor:
Information provided by:
Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00160277
First received: September 9, 2005
Last updated: January 29, 2009
Last verified: January 2009
  Purpose

The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.


Condition Intervention Phase
Hypertension
Drug: Moxonidine
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • Systolic blood pressure reduction

Secondary Outcome Measures:
  • Piggy-back pharmacoeconomic evaluation; Safety and tolerability

Estimated Enrollment: 100
Study Start Date: July 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Hypertension

Exclusion Criteria:

Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00160277

Locations
India
Site 1
Jubillee Hills Hyderabad, India
Site 2
Mangalore, India
Site 3
New Delhi, India
Sponsors and Collaborators
Solvay Pharmaceuticals
Investigators
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00160277     History of Changes
Other Study ID Numbers: S220.3.124
Study First Received: September 9, 2005
Last Updated: January 29, 2009
Health Authority: India: Indian Council of Medical Research

Keywords provided by Solvay Pharmaceuticals:
Efficacy and safety of moxonidine in Indian hypertensives

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Moxonidine
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014